DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive: In this context, a recent study aiming to evaluate CD26 expression in suspected cases of CML in the chronic phase and correlating CD26+ stem cells at baseline and their kinetics with tyrosine kinase inhibitor (TKI) treatment on a further follow-up at 12 months led to an interesting result [25].